selected publications
-
Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma.
European urology.
2020
Academic Article
GET IT
Times cited: 16 -
Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different.
Trends in immunology.
2018
Review
GET IT
Times cited: 116 -
Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes.
Clinical genitourinary cancer.
2017
Academic Article
GET IT
Times cited: 33 -
Kidney cancer in 2016: The evolution of anti-angiogenic therapy for kidney cancer.
Nature reviews. Nephrology.
2017
Review
GET IT
Times cited: 18 -
Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2016
Academic Article
GET IT
Times cited: 57 -
A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma.
The oncologist.
2016
Academic Article
GET IT
Times cited: 74 -
Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma.
British journal of cancer.
2016
Academic Article
GET IT
Times cited: 38 -
An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma.
Cancer cell.
2016
Academic Article
GET IT
Times cited: 417 -
Immune Checkpoint Therapy in Renal Cell Carcinoma.
Cancer journal (Sudbury, Mass.).
2016
Review
GET IT
Times cited: 25 -
Bevacizumab Monotherapy as Salvage Therapy for Advanced Clear Cell Renal Cell Carcinoma Pretreated With Targeted Drugs.
Clinical genitourinary cancer.
2015
Academic Article
GET IT
Times cited: 6 -
Sunitinib as a paradigm for tyrosine kinase inhibitor development for renal cell carcinoma.
Urologic oncology.
2014
Review
GET IT
Times cited: 9 - From molecular understanding to clinical advances. Nature reviews. Urology. 2013 Comment GET IT